AAAAAA

   
Results: 1-10 |
Results: 10
Effect of JTP-2942, a novel thyrotropin-releasing hormone analog, on motordeficits after chronic focal cerebral ischemia in rats
Authors: Yonemori, F Yamaguchi, T Nakayama, H Narita, K Hojo, S Tamura, A
Citation: F. Yonemori et al., Effect of JTP-2942, a novel thyrotropin-releasing hormone analog, on motordeficits after chronic focal cerebral ischemia in rats, J CEREBR B, 20(1), 2000, pp. 74-81
A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
Authors: Okamoto, H Yonemori, F Wakitani, K Minowa, T Maeda, K Shinkai, H
Citation: H. Okamoto et al., A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits, NATURE, 406(6792), 2000, pp. 203-207
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats
Authors: Shibata, T Takeuchi, S Yokota, S Kakimoto, K Yonemori, F Wakitani, K
Citation: T. Shibata et al., Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats, BR J PHARM, 130(3), 2000, pp. 495-504
Spatial cognitive performance after chronic focal cerebral ischemia in rats
Authors: Yonemori, F Yamaguchi, T Yamada, H Tamura, A
Citation: F. Yonemori et al., Spatial cognitive performance after chronic focal cerebral ischemia in rats, J CEREBR B, 19(5), 1999, pp. 483-494
Triglyceride-lowering effect of a novel insulin-sensitizing agent, JTT-501
Authors: Shibata, T Matsui, K Yonemori, F Wakitani, K
Citation: T. Shibata et al., Triglyceride-lowering effect of a novel insulin-sensitizing agent, JTT-501, EUR J PHARM, 373(1), 1999, pp. 85-91
Glucose-dependent insulinotropic effects of JTT-608, a novel antidiabetic compound
Authors: Furukawa, N Ohta, T Noguchi, T Yonemori, F Wakitani, K
Citation: N. Furukawa et al., Glucose-dependent insulinotropic effects of JTT-608, a novel antidiabetic compound, EUR J PHARM, 371(1), 1999, pp. 51-58
JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats
Authors: Ohta, T Furukawa, N Yonemori, F Wakitani, K
Citation: T. Ohta et al., JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats, EUR J PHARM, 367(1), 1999, pp. 91-99
Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative
Authors: Shibata, T Matsui, K Nagao, K Shinkai, H Yonemori, F Wakitani, K
Citation: T. Shibata et al., Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative, EUR J PHARM, 364(2-3), 1999, pp. 211-219
JTT-608 restores impaired early insulin secretion in diabetic Goto-Kakizaki rats
Authors: Ohta, T Furukawa, N Komuro, G Yonemori, F Wakitani, K
Citation: T. Ohta et al., JTT-608 restores impaired early insulin secretion in diabetic Goto-Kakizaki rats, BR J PHARM, 126(7), 1999, pp. 1674-1680
JTT-501, a novel oral antidiabetic agent, improves insulin resistance in genetic and non-genetic insulin-resistant models
Authors: Shibata, T Matsui, K Yonemori, F Wakitani, K
Citation: T. Shibata et al., JTT-501, a novel oral antidiabetic agent, improves insulin resistance in genetic and non-genetic insulin-resistant models, BR J PHARM, 125(8), 1998, pp. 1744-1750
Risultati: 1-10 |